XML 34 R10.htm IDEA: XBRL DOCUMENT

INTELLECTUAL PROPERTY LITIGATION EXPENSES	9 Months Ended
INTELLECTUAL PROPERTY LITIGATION EXPENSES	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
INTELLECTUAL PROPERTY LITIGATION EXPENSES	INTELLECTUAL PROPERTY LITIGATION EXPENSES On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries ("Abbott") to, among other things, settle all outstanding patent disputes between the companies (the “Settlement Agreement”) in cases related to transcatheter mitral and tricuspid repair products. See Note 9 for additional information. The Settlement Agreement resulted in the Company recording an estimated $367.9 million pre-tax charge and related liability in June 2020 related to past damages. In addition, the Company will incur royalty expenses through May 2024 totaling an estimated $100 million. The Company made a one-time $100.0 million payment to Abbott in July 2020, and will make quarterly payments in future years.